Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood

Award Number: R01AI117035
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2015
PERIOD OF PERFORMANCE END DATE: 02/28/2021

Group Awards By:

View Award Description

FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood - ¿ DESCRIPTION (provided by applicant): Sepsis is a life-threatening bloodstream infection that results in significant morbidity and mortality. Prompt and appropriate therapy is critical to improved outcomes, but determining the infectious micro-organism can take days. Choice of therapy is further complicated by the dramatic rise in the number of infections caused by antibiotic-resistant organisms. Rapid identification of the etiological agent along with targeted resistance information would enable optimized treatment and improved patient care. The FilmArray(tm) (FA) platform developed and manufactured by BioFire Diagnostics, LLC, is well-suited to meet the challenges of rapid sepsis diagnosis. It is a highly multiplexed, easy to use, sample to result PCR- based diagnostic system. In this project, we propose to develop and optimize a direct from blood FA panel to detect important nosocomial bacteria and their principal genetic determinants of antibiotic resistance. We will incorporate key additional technologies for optimal sensitivity and specificity. This project involves four Aims: Specific Aim 1: Develop and Optimize the FA Sepsis Direct Panel We will develop and optimize a panel for the FA system to simultaneously detect bacteria causing nosocomial infection, as well their primary determinants of antibiotic resistance. This panel will target at least 12 different Gram-negative and Gram-positive bacteria as well as 16 antibiotic resistance genes. Specific Aim 2: Develop External Enrichment Procedure of Bacteria from Blood We will develop and optimize a selective lysis and centrifugation protocol for the concentration of bacterial pathogens from large volumes of blood. With this protocol we will concentrate the viable bacteria present in up to 10 mL of whole blood to a 0.1 mL volume that can be completely introduced into a FA pouch for analysis. Specific Aim 3: Reduce Impact of Bacteria Genomic DNA (bgDNA) Background in the FA pouch We will reduce the impact of bgDNA in FA pouches by 1) working with our raw materials suppliers to lower the amount of bgDNA entering the FA pouch production line and 2) mature technology to modify sample nucleic acid sequences to create non-canonical sequences that can be recognized by unique PCR primers, effectively nullifying the impact of bgDNA. Specific Aim 4: Preclinical Evaluation of the FilmArray Sepsis Direct System in Whole Blood We use the assay system developed in specific aims 1 through 3 to test 1,000 whole blood samples from pediatric and adult patients with suspected sepsis in a preclinical evaluation. We will compare the results of FA Sepsis Direct panel testing to clinical and laboratory data for each patient.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	BIOFIRE DIAGNOSTICS, LLC	515 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Allergy and Infectious Diseases Research	000	5	10/14/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $1,166,103 )
2019	2019	BIOFIRE DIAGNOSTICS, LLC	515 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Allergy and Infectious Diseases Research	001	5	9/12/2019	NON-COMPETING CONTINUATION	$0
2019	2019	BIOFIRE DIAGNOSTICS, LLC	515 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Allergy and Infectious Diseases Research	000	5	2/7/2019	NON-COMPETING CONTINUATION	$1,166,103
														Subtotal = $1,166,103

Issue Date FY: 2018 ( Subtotal = $1,203,182 )
2018	2018	BIOFIRE DIAGNOSTICS, LLC	515 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Allergy and Infectious Diseases Research	000	4	2/22/2018	NON-COMPETING CONTINUATION	$1,203,182
														Subtotal = $1,203,182

Issue Date FY: 2017 ( Subtotal = $1,238,643 )
2017	2017	BIOFIRE DIAGNOSTICS, LLC	515 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Allergy and Infectious Diseases Research	000	3	2/21/2017	NON-COMPETING CONTINUATION	$1,238,643
														Subtotal = $1,238,643

Issue Date FY: 2016 ( Subtotal = $1,265,369 )
2016	2016	BIOFIRE DIAGNOSTICS, LLC	390 WAKARA WAY	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Allergy and Infectious Diseases Research	000	2	2/23/2016	NON-COMPETING CONTINUATION	$1,265,369
														Subtotal = $1,265,369

Issue Date FY: 2015 ( Subtotal = $1,400,168 )
2015	2015	BIOFIRE DIAGNOSTICS, LLC	390 WAKARA WAY	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Allergy and Infectious Diseases Research	000	1	3/1/2015	NEW	$1,400,168
														Subtotal = $1,400,168

Grand Total All Awards = $6,273,465

Top

All Categories

About

Search

Reports

Data Submission

Award Information

FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood

Award Number: R01AI117035

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2015

PERIOD OF PERFORMANCE END DATE: 02/28/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer